` 6996 (Antengene Corporation Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

6996
vs
Hang Seng (Hong Kong)

Over the past 12 months, has significantly outperformed Hang Seng (Hong Kong), delivering a return of 260% compared to the Hang Seng (Hong Kong)'s 38% growth.

Stocks Performance
6996 vs Hang Seng (Hong Kong)

Loading
6996
Hang Seng (Hong Kong)
Add Stock

Performance Gap
6996 vs Hang Seng (Hong Kong)

Loading
6996
Hang Seng (Hong Kong)
Difference

Performance By Year
6996 vs Hang Seng (Hong Kong)

Loading
6996
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Antengene Corporation Ltd vs Peers

Hang Seng (Hong Kong)
6996
LLY
JNJ
NOVO B
ROG
Add Stock

Antengene Corporation Ltd
Glance View

Market Cap
2.3B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 48%
Intrinsic Value
Price
Back to Top